Академический Документы
Профессиональный Документы
Культура Документы
T I M E S
A TIME COMMUNICATIONS PUBLICATION
VOL. XVIII No. 32 Monday, June 22 – 28, 2009 Pages 18 Rs.12
BAZAR.COM
Coming to terms
By Fakhri H. Sabuwala
What happened on Golden Monday, 18 May 2009, was nothing but a sentimental response to the changed paradigm. In
stock arithmetic, it is called expansion of profit to earning ratios due to a change in the market scenario. Fundamentally,
nothing had changed that day except the perception of economic growth and wellbeing of the nation. Any time a
favourable or unfavourable trigger is fired such P/E expansion or contraction occurs. The impact of this
TRADING ON TECHNICALS
Correction/sideways volatility likely
By Hitendra Vasudeo
‘Exhaustion at higher levels’ was indicated last week. The Sensex failed to cross the resistance of 15600 and violated the
support of 14500. It did manage to close above 14500 but still was below the 2 weeks low of 14526 and the week closed at
14521.
Last week, the Sensex opened at 15195.83, attained a high at 15261.03 and fell to a low of 14179.77 before it finally closed
the week at 14521.89 and thereby showed a net fall of 716 points on a week-to-week basis.
As a result of last week’s price movements, an Evening Star candlestick pattern has emerged, which indicates that the
recent rally is put to a halt and a correction/sideways movement to the preceding rally is likely to be witnessed in weeks
to come.
Wave IV- 12671 to 8799 Scrips Close Level 1 Level 2 Point Level 3 Level 4 Strength Reversal Trend
Wave V- 8799 to 21206 Value Date
Wave W-X-Y structure Stop Buy Buy Book Book
has developed Loss Price Price Profit Profit
Wave W- 21206 to 8047 BAJAJ HINDUSTAN 214.10 164.7 196.3 210.0 227.9 259.5 85.5 194.5 20-03-09
Wave A-21206 to 14677 LIC HSG FINANCE 580.40 467.5 543.3 582.1 619.1 694.9 79.9 554.9 13-03-09
Wave B-14677 to 17735 TECH MAHINDRA 760.60 541.7 684.7 751.9 827.7 970.7 77.7 648.3 08-05-09
Wave C-17735 to 8047
LARSEN & TOUBR 1496.00 1230.7 1407.7 1496.3 1584.7 1761.7 75.7 1500.8 27-03-09
MAHINDRA & MAHI 737.00 650.3 711.3 746.7 772.3 833.3 75.5 726.5 27-02-09
BEST BETS
By Saarthi
Jupiter Bioscience Ltd. (Code: 524826) Rs.61.70
Established in 1985, Jupiter Bioscience Ltd. (JBL) is a reputed pharmaceutical company specialising in the niche areas of
peptides, advanced organic chemistry, chiral chemistry and biotechnology. Led by Mr. Venkat R. Kalavakolanu, JBL
today ranks among the global top 10 players in peptide chemistry and is the only one in India with the distinction of an
integrated model of peptide pharmaceuticals. Along with its subsidiaries, the company is an end-to-end peptide solutions
provider covering the entire spectrum from key peptide raw materials to finished formulations. It has strong expertise in
manufacturing 700 different varieties of amino acids and its derivatives, which constitute the peptide building blocks. It
produces Fmoc-, Boc-, Z-protected amino acids on a large scale. Apart from offering a wide range of coupling reagents
used in the synthesis of peptides, JBL also provides generic peptide active pharmaceutical ingredients (APIs) for the
unregulated market. It has cost advantage in the large scale manufacturing of generic peptide APIs as the peptide
building blocks are produced in-house. Notably, it has capabilities in both solution and solid phase strategies for peptide
syntheses. Synthesis of cyclic peptides of variable sizes is the specialty of the company, which makes it different from
other players in the peptide market. Secondly, it is also one of the few global players manufacturing unnatural amino
acids.
In the non-peptide segment, it manufactures a several organic APIs covering a wide range of therapeutic segments
including anti-hypertensives,
antidepressants, antispasmodics, anti-
allergics and anti-ulcer drugs. It also For F&O Traders
produces dozens of drug intermediates
and fine chemicals that are eventually Profitrak Daily Fresh Futures
supplied to reputed pharmaceutical
Highlights of Profitrak Daily Fresh Futures:
companies on a regular basis. It even
1) One Buy Per Day (If available as per our ‘Buy’ criteria)
supplies two veterinary (animal) drugs How a ‘Buy’ is decided?
in the anti-helmintics segment. Besides, ‘Fresh Buy’ as per our trading signal. But the trading signal must be
it is active in the lucrative and rapidly supported by increase in open interest and volumes and the candle
growing CRAMS segment, as API movement (Close>Open) is positive. The stock with the highest relative
manufacturing companies in developed strength will be selected as the daily fresh buy from the F&O segment.
countries seek contract R&D and 2) Follow up on an earlier Uptrend or ‘Buy’. These stock futures remain
manufacturing partners in India to in an uptrend till the prices are above the Daily Reversal Value.
avail of the cost advantage. Moreover, 3) Exit Long position indication
JBL has capabilities to undertake 4) One Sell Per Day (if available as per our ‘Sell’ criteria)
customised synthesis of amino acid 5) Follow Up of earlier Downtrend or ‘Sell’
derivatives, bulk peptides and new 6) Exit Short indication
chemical entities (NCE) for its clientele. Subscription: Rs.4000 per month.
Broadly, the company has segmented Visit www.moneytimes.in for sample copy.
its product profile in three groups For further details contact us on 022-22654805 or email us at
namely ‘Peptides’, ‘Drug moneytimes@vsnl.com
Disclaimer: Investment recommendations made in Money Times are for information purposes only and derived from sources
that are deemed to be reliable but their accuracy and completeness are not guaranteed. Money Times or the analyst/writer does
not accept any liability for the use of this column for the buying or selling of securities. Readers of this column who buy or sell
securities based on the information in this column are solely responsible for their actions. The author, his company or his
acquaintances may/may not have positions in the above mentioned scrip.
Name: ________________________________________________________________
Address: ______________________________________________________________
______________________________________________________________________
Email: ________________________________________________________________
Are you a Investor Trader Broker/Sub-Broker Investment Advisor Banker